VK2735: a smaller developer is testing several treatment patterns
VK2735 is Viking Therapeutics' investigational dual GLP-1/GIP agonist.
VK2735 is Viking Therapeutics' investigational dual GLP-1/GIP agonist. Injectable and oral development programs should remain linked to the same compound identity while retaining their different dosing and study designs. Viking's July 29 update described full enrollment of the weekly injectable Phase 3 VANQUISH program and an oral Phase 3 start planned for the fourth quarter; that planned timing is not evidence that the trial has already begun. Viking July update.
VANQUISH-1 studies adults without type 2 diabetes; VANQUISH-2 addresses the diabetes population. Both compare weekly treatment with placebo and assess weight change at 78 weeks. Their current registry states are active but not recruiting. Keeping those populations separate is essential when later results arrive. VANQUISH-1, VANQUISH-2.
A separate September 22 announcement explored less frequent maintenance dosing after initial weekly treatment. It belongs in a dated development entry, rather than being presented as a replacement for the pivotal Phase 3 evidence. The study's short maintenance period and small treatment groups limit the conclusions about durability and tolerability.
Viking's resource position deserves more attention than the balance sheet of a diversified drugmaker. Its June filing shows rising operating cash use as development expands; the company account (below) keeps investments, restricted cash, reported loss and cash use distinct. Viking described VK2735 as wholly owned in July. No compound-specific development partner is established in sources reviewed through September 22, 2026, and a shelf registration is financing capacity rather than completed funding.
Viking Therapeutics — company resources
At June 30, Viking reported $125.8 million of cash and equivalents and $375.9 million of short-term investments, totaling $501.7 million. Restricted cash of $0.2 million is separate. First-half operating cash use was $239.1 million, compared with $99.4 million a year earlier; the net loss was $286.3 million. The balance sheet lists lease obligations but no separate borrowing balance. Development spending and the cost of preparing larger trials make the cash-flow trend relevant. A July shelf registration represents financing capacity, not proceeds already received. Form 10-Q filed July 29, shelf prospectus.
About this account
Published September 23, 2026. Company and regulatory disclosures are covered through September 22; trial-registry records were retrieved September 23. Earlier developments are reconstructed from dated primary sources. Registry status, sponsor-reported results and regulatory decisions are distinguished in the account. Company figures retain their reporting periods; corporate cash is not a compound-specific funding commitment.